China Resources Boya Bio pharmaceutical Group Co Ltd Total Liabilities
China Resources Boya Bio pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has total liabilities worth CN¥942.80 Million CNY (≈ $137.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check China Resources Boya Bio pharmaceutical (300294) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
Total liabilities of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025. This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore China Resources Boya Bio pharmaceutical (300294) long-term investment share to see how much of total assets are deployed in long-term investments.
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥823.87 Million |
|
Anhui Water Resources Development Co Ltd
SHG:600502
|
China | CN¥194.79 Billion |
|
Shenzhen Clou Electronics Co Ltd
SHE:002121
|
China | CN¥7.52 Billion |
|
Corbion N.V.
F:CSU
|
Germany | €674.30 Million |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥6.18 Billion |
|
ZINKA LOGISTICS SOL LTD
NSE:BLACKBUCK
|
India | Rs3.14 Billion |
|
Chengdu Gas Group Co Ltd
SHG:603053
|
China | CN¥3.27 Billion |
|
Shinyoung HappyTomorrow No.5 Special Purpose Acquisition Company
KQ:323280
|
Korea | ₩65.35 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300294 total assets.
Liquidity & Leverage Metrics
China Resources Boya Bio pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
China Resources Boya Bio pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Boya Bio pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual total liabilities of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.16 Billion ≈ $170.47 Million |
+27.54% |
| 2024-12-31 | CN¥913.38 Million ≈ $133.66 Million |
+79.77% |
| 2023-12-31 | CN¥508.07 Million ≈ $74.35 Million |
-32.11% |
| 2022-12-31 | CN¥748.35 Million ≈ $109.51 Million |
+6.71% |
| 2021-12-31 | CN¥701.30 Million ≈ $102.62 Million |
-27.41% |
| 2020-12-31 | CN¥966.08 Million ≈ $141.37 Million |
-23.82% |
| 2019-12-31 | CN¥1.27 Billion ≈ $185.56 Million |
-2.65% |
| 2018-12-31 | CN¥1.30 Billion ≈ $190.61 Million |
+9.89% |
| 2017-12-31 | CN¥1.19 Billion ≈ $173.45 Million |
+312.58% |
| 2016-12-31 | CN¥287.30 Million ≈ $42.04 Million |
+2.57% |
| 2015-12-31 | CN¥280.11 Million ≈ $40.99 Million |
+198.30% |
| 2014-12-31 | CN¥93.90 Million ≈ $13.74 Million |
-40.51% |
| 2013-12-31 | CN¥157.85 Million ≈ $23.10 Million |
+511.75% |
| 2012-12-31 | CN¥25.80 Million ≈ $3.78 Million |
-62.32% |
| 2011-12-31 | CN¥68.48 Million ≈ $10.02 Million |
-29.97% |
| 2010-12-31 | CN¥97.79 Million ≈ $14.31 Million |
-35.64% |
| 2009-12-31 | CN¥151.93 Million ≈ $22.23 Million |
+77.72% |
| 2008-12-31 | CN¥85.49 Million ≈ $12.51 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more